Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Clinical utility of cerebrospinal fluid-derived circular RNAs in lung adenocarcinoma patients with brain metastases

Fig. 1

RNA profiling with cerebrospinal fluid, plasma, and tumor-tissue samples in lung cancer patients with brain metastasis. A Comparison of the number of detected circRNAs in cerebrospinal fluid, plasma, and tumor-tissue samples (*: p-value < 0.05). B The distribution of expression abundance of detected circRNAs in cerebrospinal fluid, plasma, and tumor-tissue samples. C The distribution of the ratio of expression of detected circRNAs to their parental mRNAs in cerebrospinal fluid, plasma, and tumor-tissue samples. D Log2-transformed number of shared circRNAs between different samples from the same or different patient(s) (patient 1 and 20: RNA-seq data not available for cerebrospinal fluid samples, patient 4, 7, 9, 11, 18 and 19: RNA-seq data not available for tumor-tissue samples). E Number of shared circRNAs among all 3 different samples (cerebrospinal fluid, plasma, and tumor-tissue) for individual patient

Back to article page